Literature DB >> 22706836

Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.

Daniel Tarsy1.   

Abstract

In early stages, Parkinson disease typically begins with asymmetric or unilateral motor symptoms due to combinations of mild bradykinesia, rigidity, and tremor. In most cases, with progression, signs of more generalized bradykinesia appear, which include facial masking, reduced voice volume, and slowing of activities of daily living. In more advanced Parkinson disease, other disabling manifestations may follow, such as impaired balance, gait freezing, falls, speech disturbance, and cognitive impairment. Levodopa is the most effective medical treatment for Parkinson disease. However, motor complications uniquely related to levodopa treatment may emerge that may be difficult to manage. These include fluctuating levodopa responses and involuntary movements and postures known as dyskinesia and dystonia. Medication adjustments are usually effective, but in some cases surgical intervention with deep brain stimulation becomes necessary to alleviate motor complications. The case of Mr L, a man with an 11-year history of Parkinson disease, illustrates these emerging motor complications and the manner in which they may be managed both medically and surgically.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706836     DOI: 10.1001/jama.2012.4829

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  7 in total

Review 1.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 2.  Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.

Authors:  Song Li; Jie Dong; Cheng Cheng; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2016-08-11       Impact factor: 3.575

Review 3.  Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease.

Authors:  Nrupa Borkar; Huiling Mu; René Holm
Journal:  Asian J Pharm Sci       Date:  2017-12-06       Impact factor: 6.598

4.  Analysis of master transcription factors related to Parkinson's disease through the gene transcription regulatory network.

Authors:  Li Wei; Fei He; Wen Zhang; Wenhua Chen; Bo Yu
Journal:  Arch Med Sci       Date:  2019-10-29       Impact factor: 3.318

Review 5.  Regulated cell death: discovery, features and implications for neurodegenerative diseases.

Authors:  Juntao Cui; Suhan Zhao; Yinghui Li; Danyang Zhang; Bingjing Wang; Junxia Xie; Jun Wang
Journal:  Cell Commun Signal       Date:  2021-12-18       Impact factor: 5.712

Review 6.  Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.

Authors:  Jie Dong; Yanhua Cui; Song Li; Weidong Le
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

7.  Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease.

Authors:  George D Mellick; Peter M Visscher; Jacob Gratten; Costanza L Vallerga; Futao Zhang; Javed Fowdar; Allan F McRae; Ting Qi; Marta F Nabais; Qian Zhang; Irfahan Kassam; Anjali K Henders; Leanne Wallace; Grant Montgomery; Yu-Hsuan Chuang; Steve Horvath; Beate Ritz; Glenda Halliday; Ian Hickie; John B Kwok; John Pearson; Toni Pitcher; Martin Kennedy; Steven R Bentley; Peter A Silburn; Jian Yang; Naomi R Wray; Simon J G Lewis; Tim Anderson; John Dalrymple-Alford
Journal:  Nat Commun       Date:  2020-03-06       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.